Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ACLX NASDAQ:KYMR NASDAQ:PTGX NASDAQ:TRML On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACLXArcellx$86.80-1.8%$75.42$47.86▼$107.37$4.81B0.31537,581 shs1.30 million shsKYMRKymera Therapeutics$57.21+0.3%$47.00$19.44▼$59.00$4.09B2.26924,586 shs736,904 shsPTGXProtagonist Therapeutics$87.00+29.8%$60.08$33.31▼$93.25$5.41B2.21.34 million shs7.06 million shsTRMLTourmaline Bio$47.87+0.0%$34.96$11.56▼$48.27$1.23B2.27758,068 shs737,152 shsThese 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACLXArcellx0.00%+2.03%+11.74%+25.83%+4.65%KYMRKymera Therapeutics0.00%-1.19%+23.83%+28.62%+32.00%PTGXProtagonist Therapeutics0.00%+34.20%+45.78%+64.15%+96.92%TRMLTourmaline Bio0.00%-0.06%+0.57%+166.24%+76.12%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACLXArcellx$86.80-1.8%$75.42$47.86▼$107.37$4.81B0.31537,581 shs1.30 million shsKYMRKymera Therapeutics$57.21+0.3%$47.00$19.44▼$59.00$4.09B2.26924,586 shs736,904 shsPTGXProtagonist Therapeutics$87.00+29.8%$60.08$33.31▼$93.25$5.41B2.21.34 million shs7.06 million shsTRMLTourmaline Bio$47.87+0.0%$34.96$11.56▼$48.27$1.23B2.27758,068 shs737,152 shsThese 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACLXArcellx0.00%+2.03%+11.74%+25.83%+4.65%KYMRKymera Therapeutics0.00%-1.19%+23.83%+28.62%+32.00%PTGXProtagonist Therapeutics0.00%+34.20%+45.78%+64.15%+96.92%TRMLTourmaline Bio0.00%-0.06%+0.57%+166.24%+76.12%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACLXArcellx 2.87Moderate Buy$112.6929.83% UpsideKYMRKymera Therapeutics 2.95Moderate Buy$61.267.08% UpsidePTGXProtagonist Therapeutics 2.83Moderate Buy$68.83-20.88% DownsideTRMLTourmaline Bio 2.00Hold$45.65-4.64% DownsideCurrent Analyst Ratings BreakdownLatest TRML, ACLX, KYMR, and PTGX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/9/2025ACLXArcellxCantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingNeutral$88.0010/9/2025ACLXArcellxCantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold$88.0010/8/2025ACLXArcellxWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025KYMRKymera TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025PTGXProtagonist TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D+)10/8/2025PTGXProtagonist TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$80.0010/8/2025TRMLTourmaline BioWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/7/2025PTGXProtagonist TherapeuticsJohnson RiceSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$74.0010/1/2025KYMRKymera TherapeuticsOppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$53.00 ➝ $63.009/30/2025KYMRKymera TherapeuticsTruist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$53.00 ➝ $68.009/27/2025ACLXArcellxWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)(Data available from 10/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACLXArcellx$107.94M44.60N/AN/A$8.41 per share10.32KYMRKymera Therapeutics$47.07M86.90N/AN/A$12.90 per share4.43PTGXProtagonist Therapeutics$434.43M12.46$4.52 per share19.26$11.33 per share7.68TRMLTourmaline BioN/AN/AN/AN/A$11.71 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACLXArcellx-$107.35M-$3.42N/AN/AN/A-329.93%-43.04%-27.41%11/6/2025 (Estimated)KYMRKymera Therapeutics-$223.86M-$3.47N/AN/AN/A-616.03%-31.60%-27.12%10/30/2025 (Estimated)PTGXProtagonist Therapeutics$275.19M$0.70124.29N/AN/A24.88%8.12%7.41%11/6/2025 (Estimated)TRMLTourmaline Bio-$73.21M-$3.43N/AN/AN/AN/A-30.50%-29.63%11/6/2025 (Estimated)Latest TRML, ACLX, KYMR, and PTGX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails11/6/2025Q3 2025ACLXArcellx-$1.00N/AN/AN/A$11.24 millionN/A11/6/2025Q3 2025PTGXProtagonist Therapeutics-$0.59N/AN/AN/A$5.41 millionN/A11/6/2025Q3 2025TRMLTourmaline Bio-$0.96N/AN/AN/AN/AN/A10/30/2025Q3 2025KYMRKymera Therapeutics-$0.73N/AN/AN/AN/AN/A8/13/2025Q2 2025TRMLTourmaline Bio-$0.94-$0.90+$0.04-$0.90N/AN/A8/11/2025Q2 2025KYMRKymera Therapeutics-$0.83-$0.95-$0.12-$0.95$17.37 million$11.48 million8/7/2025Q2 2025ACLXArcellx-$1.03-$0.94+$0.09-$0.94$16.76 million$7.55 million8/6/2025Q2 2025PTGXProtagonist Therapeutics-$0.53-$0.55-$0.02-$0.55$8.32 million$5.55 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthACLXArcellxN/AN/AN/AN/AN/AKYMRKymera TherapeuticsN/AN/AN/AN/AN/APTGXProtagonist TherapeuticsN/AN/AN/AN/AN/ATRMLTourmaline BioN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACLXArcellxN/A3.813.81KYMRKymera TherapeuticsN/A8.328.32PTGXProtagonist TherapeuticsN/A16.9716.97TRMLTourmaline BioN/A24.6824.68Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACLXArcellx96.03%KYMRKymera TherapeuticsN/APTGXProtagonist Therapeutics98.63%TRMLTourmaline Bio91.89%Insider OwnershipCompanyInsider OwnershipACLXArcellx8.35%KYMRKymera Therapeutics16.01%PTGXProtagonist Therapeutics4.90%TRMLTourmaline Bio13.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableACLXArcellx8055.46 million50.83 millionOptionableKYMRKymera Therapeutics17071.50 million60.05 millionOptionablePTGXProtagonist Therapeutics12062.21 million59.16 millionOptionableTRMLTourmaline Bio4425.69 million22.35 millionOptionableTRML, ACLX, KYMR, and PTGX HeadlinesRecent News About These CompaniesWeiss Ratings Reaffirms "Sell (D-)" Rating for Tourmaline Bio (NASDAQ:TRML)October 9 at 12:35 AM | marketbeat.comTourmaline Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Tourmaline Bio, Inc. - TRMLOctober 6, 2025 | businesswire.comTourmaline Bio, Inc. (NASDAQ:TRML) Sees Large Decline in Short InterestOctober 5, 2025 | marketbeat.comTourmaline Bio, Inc. (NASDAQ:TRML) Receives $45.65 Consensus Price Target from AnalystsOctober 5, 2025 | americanbankingnews.comTourmaline Bio, Inc. (NASDAQ:TRML) Given Average Rating of "Hold" by AnalystsOctober 2, 2025 | marketbeat.comTourmaline Bio (TRML) Price Target Decreased by 14.70% to 48.90September 30, 2025 | msn.comTourmaline Bio (NASDAQ:TRML) Sets New 52-Week High - Here's WhySeptember 29, 2025 | marketbeat.comNovartis announces commencement of tender offer to acquire Tourmaline BioSeptember 29, 2025 | globenewswire.comTourmaline Bio (NASDAQ:TRML) Reaches New 52-Week High - Here's WhySeptember 22, 2025 | marketbeat.comTourmaline Bio, Inc. $TRML Stock Holdings Decreased by Goldman Sachs Group Inc.September 22, 2025 | marketbeat.comWesbanco Bank Inc. Makes New $416,000 Investment in Tourmaline Bio, Inc. $TRMLSeptember 17, 2025 | marketbeat.comTourmaline Bio (NASDAQ:TRML) Reaches New 12-Month High - Here's WhySeptember 16, 2025 | marketbeat.comTourmaline Bio (NASDAQ:TRML) Earns "Market Perform" Rating from BMO Capital MarketsSeptember 16, 2025 | marketbeat.comSHAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Tourmaline Bio, Inc. (NASDAQ: TRML)September 15, 2025 | prnewswire.comBMO Capital Downgrades Tourmaline Bio (TRML)September 15, 2025 | msn.comTourmaline Bio (TRML): Assessing Valuation as Market Interest GrowsSeptember 14, 2025 | finance.yahoo.comTourmaline Bio (NASDAQ:TRML) Receives "Neutral" Rating from Piper SandlerSeptember 13, 2025 | marketbeat.comTourmaline Bio Updates Executive Severance PlanSeptember 12, 2025 | tipranks.comTourmaline Bio (NASDAQ:TRML) Sees Strong Trading Volume - Here's What HappenedSeptember 12, 2025 | marketbeat.comTruist Financial Reaffirms Hold Rating for Tourmaline Bio (NASDAQ:TRML)September 12, 2025 | marketbeat.comTourmaline Bio (NASDAQ:TRML) Receives Neutral Rating from GuggenheimSeptember 12, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTRML, ACLX, KYMR, and PTGX Company DescriptionsArcellx NASDAQ:ACLX$86.80 -1.59 (-1.80%) Closing price 10/10/2025 04:00 PM EasternExtended Trading$86.80 0.00 (0.00%) As of 10/10/2025 05:33 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Arcellx, Inc., together with its subsidiary, engages in the development of various immunotherapies for patients with cancer and other incurable diseases in the United States. The company's lead ddCAR product candidate is anitocabtagene autoleucel, which is in phase 2 clinical trial for the treatment of patients with relapsed or refractory multiple myeloma (rrMM). It also develops ACLX-001, a product candidate in Phase 1 clinical trials targeting BCMA to treat rrMM; and ACLX-002, which is in Phase 1 clinical trials that targets CD123 for treating relapsed or refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). In addition, the company's preclinical product includes ACLX-003 for the treatment of AML and MDS. Further, it focuses on the development of product candidates for solid tumor programs. It has a strategic alliance with Kite Pharma, Inc. to co-develop and co-commercialize anitocabtagene autoleucel. The company was formerly known as Encarta Therapeutics, Inc. and changed its name to Arcellx, Inc. in January 2016. Arcellx, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.Kymera Therapeutics NASDAQ:KYMR$57.21 +0.19 (+0.33%) Closing price 10/10/2025 04:00 PM EasternExtended Trading$57.18 -0.04 (-0.06%) As of 10/10/2025 07:03 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company develops STAT6, a Type 2 inflammation in allergic diseases; and TYK2, a treatment for inflammatory bowel disease, psoriasis, psoriatic arthritis, and lupus. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.Protagonist Therapeutics NASDAQ:PTGX$87.00 +19.96 (+29.77%) Closing price 10/10/2025 04:00 PM EasternExtended Trading$88.46 +1.46 (+1.68%) As of 10/10/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis. The company has a license and collaboration agreement with Takeda to commercialize rusfertide; and JNJ Innovative Medicines to co-develop Interleukin-23 receptor antagonist compound JNJ-2113. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.Tourmaline Bio NASDAQ:TRML$47.87 +0.02 (+0.04%) Closing price 10/10/2025 04:00 PM EasternExtended Trading$47.54 -0.34 (-0.70%) As of 10/10/2025 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Tourmaline Bio, Inc. operates as a clinical biotechnology company that develops medicines for patients with life-altering immune and inflammatory diseases. It develops TOUR006, a human anti-IL-6 monoclonal antibody that selectively binds to interleukin-6, a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders. The company's development pipeline comprises medicines and therapies for the atherosclerotic cardiovascular disease (ASCVD) and thyroid eye disease (TED). The company was formerly known as Tourmaline Bio, LLC and changed its name to Tourmaline Bio, Inc. in September 2022. Tourmaline Bio, Inc. was founded in 2021 and is headquartered in New York, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Broadcom Gets Second $420 Target as CPO Win Boosts Outlook AST SpaceMobile's Big Win: Shares Soar on New Deal With Verizon Microsoft 365 Premium Marks the Next Phase of AI Monetization 3 Reasons to Buy Sprouts Farmers Market Ahead of Earnings Bassett Furniture: Buy Now, Sit Back, and Collect Dividends Why Amazon’s Prime Day May Be the Catalyst for a Year-End Rally PepsiCo’s Deep Discount Will Soon Evaporate: Buy It While You Can Bargain Alert: DraftKings Is the Most Oversold It’s Ever Been Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
